



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



ELSEVIER

# Gastroenterología y Hepatología

[www.elsevier.es/gastroenterologia](http://www.elsevier.es/gastroenterologia)


## SCIENTIFIC LETTER

### Probable autoimmune hepatitis reactivated after COVID-19 vaccination



### Probable hepatitis autoinmune reactivada tras vacunación COVID-19



COVID-19 vaccine has recently been related to few cases of autoimmune hepatitis (AIH),<sup>1–3</sup> raising the question whether there exists a causal relationship between COVID-19 vaccination and the development of AIH in predisposed patients. Several autoimmune diseases have been reported in association with vaccines. In fact, AIH triggered by vaccination for other diseases has also been described.<sup>4</sup>

We present herein a 46-year-old Caucasian woman that was sent to the hepatology clinics of our hospital in January 2018 for mild hypertransaminasemia. She had a medical history of hypothyroidism treated with levothyroxine, and chronic iron deficiency anemia which had been attributed to menstrual bleeding. The patient was asymptomatic but a routine blood test found AST 122 U/L, ALT 157 U/L with normal GGT, alkaline phosphatase and bilirubin; hemoglobin 9.3 g/dL, with normal coagulation. Abdominal ultrasound was normal and serologies were negative for hepatitis A, B and C, Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV) type 1 and 2, varicella-zoster virus (VVZ) and HIV. Antinuclear antibody (ANA) was positive (1:160; rods and rings pattern). Other antibodies (i.e. anti-mitochondrial, anti-smooth muscle, liver-kidney microsomal, antitransglutaminase) were negative. Serum protein electrophoresis showed gammaglobulin of 19.9%. Iron deficiency was found, with a ferritin of 8.4 ng/mL and a transferrin saturation of 4.8%. Ceruloplasmin, TSH and immunoglobulins were normal. Due to chronic anemia, mild inespecific gastrointestinal symptoms in the past and abnormal liver function tests, an upper GI endoscopy was performed with duodenal biopsies showing normal villi with not raised intraepithelial CD3+ lymphocytes. Genetic study resulted positive HLA-DRB1\*03 and 04, indicating a susceptibility to AIH, and positive HLA DQ2 and DQ8 for celiac disease. Transient elastography result was 7.8 KPa. We followed the patient in our hepatology clinic with routine blood tests every six months, always finding normal liver function tests during a 2-year follow-up. The patient received the first Vaxzevria COVID-19 vaccine on March 2021. In a sched-

uled control with laboratory test performed 3 weeks after vaccination we found AST 241 U/L, ALT 353 U/L, GGT 44 U/L and alkaline phosphatase 135 U/L with normal bilirubin and coagulation. Total IgG was 2016 mg/dL. Viral acute hepatitis was ruled out and there was no history of exposure to hepatotoxic drugs. A liver biopsy was performed and the findings were compatible with AIH (Fig. 1A–C). The Revised Original Score for AIH pretreatment was 18 and the simplified criteria for the diagnosis of AIH was 7, both indicating definite AIH. Prednisone was initiated at a dose of 30 mg daily with a rapid improvement after 2 weeks of treatment (Fig. 1D), so prednisone was tapered to 20 mg and azathioprine was added to treatment at a dose of 50 mg daily.

Recently, immune thrombocytopenia cases developing after vaccination for this disease have been published, suggesting that COVID-19 vaccines may induce autoimmune diseases.<sup>5</sup> In the last few months some cases of AIH after COVID-19 vaccination have been published, related to both mRNA vaccines<sup>1,2</sup> and viral-vector vaccines.<sup>3</sup> Our patient presented with acute AIH following Vaxzevria COVID-19 vaccine, a viral vector vaccine. Special consideration deserves the fact that in this case there was a previous medical history of abnormal liver function tests 2 years before with spontaneous normalization, and a positive genetic study for AIH predisposition, so it is probable that the patient had an AIH controlled without treatment and the vaccine triggered a flare of the disease. However, we cannot prove whether COVID-19 vaccine was the trigger of a new bout of AIH or if it is a casual association. Moreover, it could be a case of drug induced autoimmune liver disease (DIALD), as the histology is no pathognomonic distinguishing DIALD and AIH. In regard with this, our patient has initiated azathioprine and is tapering prednisone, so additional follow up will be crucial to better understand the process.

To sum up, we present the case of a 46-year-old woman with a probable AIH controlled without treatment, who presented with a flare of the disease after COVID-19 vaccination. Distinguishing vaccine-induced autoimmune liver disease from coincidental autoimmune liver disease presenting soon after vaccination is not possible at this time. The report of this case reinforces the message that vaccines against COVID-19 could either induce AIH or lead to a flare of the disease, and should encourage us to remain vigilant.



**Figure 1** Histological and biochemical findings. (A, B) H&E stain low-magnification ( $\times 20$  and  $\times 40$  respectively) shows lymphoplasmacytic portal infiltrate with focal disruption of the limiting plate. No evidence was found of histologic cholestasis, fibrosis or iron deposit. (C) Immunohistochemical study of plasma cells expressing CD38. (D) Biochemical trend of plasma ALT and AST over time.

## Authors' contributions

ST: writing of the manuscript and revision of the final version of the manuscript. AC: patient care and revision of the

final version of the manuscript. MG: pathology reading and revision of the final version of the manuscript. EZ: patient care and revision of the final version of the manuscript.

## Financial support

None.

## Conflicts of interest

None.

## References

- Bril F, Al Diffalha S, Dean M, Fettig DM. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: causality or casualty? *J Hepatol*. 2021. S0168-8278(21)00237-3.
- Londoño MC, Gratacós-Ginès J, Sáez-Peña J. Another case of autoimmune hepatitis after SARS-CoV-2 vaccination. Still causality? *J Hepatol*. 2021. S0168-8278(21)00417-7.
- Rela M, Jothimani D, Vij M, Rajakumar A, Rammohan A. Autoimmune hepatitis following COVID vaccination. *J Autoimmun*. 2021;123:102688.
- Muratori P, Serio I, Lalanne C, Lenzi M. Development of autoimmune hepatitis after influenza vaccination; trigger or killer? *Clin Res Hepatol Gastroenterol*. 2019;43:e95–6.
- Lee EJ, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, et al. Thrombocytopenia following pfizer and moderna SARS-CoV-2 vaccination. *Am J Hematol*. 2021;96:534–7.

Silvia Torrente<sup>a,\*</sup>, Agustín Castiella<sup>a</sup>, Maddi Garmendia<sup>b</sup>, Eva Zapata<sup>a</sup>

<sup>a</sup>Department of Gastroenterology and Hepatology, Donostia University Hospital, Spain

<sup>b</sup>Department of Pathology, Donostia University Hospital, Spain

Corresponding author.

E-mail address: [siltorrenteir@gmail.com](mailto:siltorrenteir@gmail.com) (S. Torrente).